Go to Page # Page of 105
loading

Biotech Business: Monetizing IP & New Financing Paradigms

 Lynne Zydowsky, Zydowsky Consultants
  24th-Nov-2008
Description: Emergence of new financing paradigms Continued issues with regulatory approval The Genentech Model for Monetizing IP Top BioTech Companies Biotech business cycles Generations of Drug Discovery Genomic Revolution Systems Biology Revolution: Computational methods and capabilities allow for a better understanding/prediction of complex biological systems 15 Top Blockbuster Drugs Top 20 Biotech Drugs Blockbuster Model: Issues Industrialized R&D Drug Development Costs R&D Productivity Innovation Gap.
Views: 2161
Domain: Medical
Category: Biotech/Pharma
Contents:
The Business of Biotech October 16, 2006

Lynne Zydowsky Zydowsky Consultants

Agenda
� Overview of the Biotechnology Market � Industry overview and critical issues � Current and future markets/disease indications � Economics and risks of drug development � Future drivers of the Industry Viable Business Models and Strategies � ... See more

The Business of Biotech

Emergence of new financing paradigms Continued issues with regulatory approval The Genentech Model for Monetizing IP Top BioTech Companies Biotech business cycles Generations of Dr

...
24 November, 2008